As both enzymes are molecular targets for cancer therapy, with specific inhibitors of FASN activity (7,38) or by inducing LPL activity in non-cancer tissues by peroxisome proliferator-activated receptor γ agonists (39,40), PEMT may also be a promising diagnostic and therapeutic target. Here, FASN is linked to cancer.